NDAINTRAVENOUSSOLUTIONPriority Review
Approved
May 2007
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Clinical Trials (5)
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Started Jul 2015
16 enrolled
Lymphoblastic Leukemia, Acute, ChildhoodLymphoblastic LymphomaPeripheral T-cell Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Started Jun 2015
7 enrolled
Recurrent LymphomaRefractory LymphomaSolid Tumours+1 more
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Started Dec 2014
10 enrolled
Brain Tumor, RecurrentGlioblastomaAnaplastic Astrocytoma+2 more
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Started Feb 2013
73 enrolled
GanglioneuroblastomaRecurrent Neuroblastoma
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Started Feb 2013
41 enrolled
Renal Cell CarcinomaNonclear CellTemsirolimus Resistance
Loss of Exclusivity
LOE Date
Nov 10, 2032
81 months away
Patent Expiry
Nov 10, 2032
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8026276 | Jan 20, 2026Expired | Product | — |
| 8026276*PED | Jul 20, 2026 | — | |
| 8791097 | May 10, 2032 | U-1550 | |
| 8791097*PED | Nov 10, 2032 | — |